Source: Canfite
Can-Fite BioPharma Ltd. announced positive results from a multicenter clinical study conducted by its Veterinary partner Vetbiolix, evaluating Piclidenoson for treating canine osteoarthritis. The study demonstrated that oral administration of Piclidenoson (500 µg/kg twice daily) significantly improved mobility, reduced pain, and alleviated symptoms as assessed through the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire, Visual Analog Scale (VAS), and Numerical Rating Score (NRS). These results mark a dose- and time-dependent improvement in clinical outcomes.
The success allows Vetbiolix to potentially in-license Piclidenoson, committing to upfront payments, milestones, and royalties upon regulatory approval. Unlike current canine osteoarthritis treatments, such as NSAIDs with significant side effects or injectable disease-modifying drugs, Piclidenoson offers a safer and effective oral alternative. With the canine osteoarthritis market projected to reach $3 billion by 2028, Can-Fite sees this as a promising opportunity to bring Piclidenoson to market faster, benefiting canines and generating near-term revenues.
Read the full story HERE: https://ir.canfite.com/news-events/press-releases/detail/1058/positive-results-from-osteoarthritis-clinical-study-in-dogs